A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

被引：1

作者：

Liu, Wei ^{[1
]}

Huang, Yunhong ^{[2
]}

Yang, Haiyan ^{[3
]}

Li, Zhiming ^{[4
]}

Cai, Zhen ^{[5
]}

Wang, Zhen ^{[6
]}

Liu, Lihong ^{[7
]}

Guo, Ye ^{[8
]}

Liu, Ligen ^{[9
]}

Huang, Rui ^{[10
]}

Ye, Xu ^{[11
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, Tianjin, Peoples R China

[2] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Peoples R China

[3] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[4] State Key Lab Oncol South China, Guangzhou, Peoples R China

[5] Zhejiang Univ, Sch Med, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, Hangzhou, Peoples R China

[6] Linyi Canc Hosp, Linyi, Peoples R China

[7] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China

[8] Shanghai East Hosp, Shanghai, Peoples R China

[9] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai, Peoples R China

[10] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China

[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177550

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Jin, Jie
Cen, Hong
Zhou, Keshu
Xu, Xiaohong
Li, Fei
Yang, Haiyan
Li, Zhiming
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
Shu, Yang
Li, Fei
Wang, Zhen
BLOOD, 2021, 138
[2] A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma
Jin, Jie
Cen, Hong
Zhou, Keshu
Xu, Xiaohong
Li, Fei
Wu, Tao
Yang, Haiyan
Wang, Zhen
Li, Zhiming
Huang, Wenyang
Bao, Hanying
Xu, Zusheng
Qiu, Lugui
CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4593 - 4600
[3] Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study
Li, Zhiming
Sun, Peng
Cen, Hong
Yang, Haiyan
Huang, Rui
Cai, Zhen
Gu, Xuekui
BLOOD, 2023, 142
[4] Pirtobrutinib monotherapy in patients with relapsed/refractory B-cell malignancies intolerant to prior covalent BTK inhibitor
Munir, Talha
Shah, Nirav N.
Wang, Michael
Brown, Jennifer R.
Patel, Krish
Woyach, Jennifer
Wierda, William G.
Ujjani, Chaitra S.
Eyre, Toby A.
Zinzani, Pier Luigi
Alencar, Alvaro J.
Gastinne, Thomas
Ghia, Paolo
Lamanna, Nicole
Hoffmann, Marc S.
Patel, Manish R.
Flinn, Ian
Gerson, James N.
Ma, Shuo
Coombs, Catherine C.
Cheah, Chan Y.
Lech-Maranda, Ewa
Fakhri, Bita
Kim, Won Seog
Barve, Minal A.
Cohen, Jonathon B.
Jurczak, Wojciech
Thompson, Meghan C.
Roeker, Lindsey E.
Bao, Katherine
Cangemi, Nicholas A.
Kherani, Jennifer F.
Walgren, Richard A.
Han, Hongmei
Ruppert, Amy S.
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 13 - 13
[5] A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Collins, Graham P.
Clevenger, Tracy N.
Burke, Kathleen A.
Yang, Buyue
MacDonald, Alex
Cunningham, David
Fox, Christopher P.
Goy, Andre
Gribben, John
Nowakowski, Grzegorz S.
Roschewski, Mark
Vose, Julie M.
Vallurupalli, Anusha
Cheung, Jean
Raymond, Amelia
Nuttall, Barrett
Stetson, Dan
Dougherty, Brian A.
Schalkwijk, Stein
Carnevalli, Larissa S.
Willis, Brandon
Tao, Lin
Harrington, Elizabeth A.
Hamdy, Ahmed
Izumi, Raquel
Pease, J. Elizabeth
Frigault, Melanie M.
Flinn, Ian
LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2625 - 2636
[6] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Shadman, Mazyar
Sharman, Jeff P.
Levy, Moshe Y.
Misleh, Jamal
Zafar, Syed F.
Freeman, Benjamin B.
Burke, John M.
Cultrera, Jennifer L.
Yimer, Habte A.
Chen, Dih-Yih
Zhang, Xiaoping
Cohen, Aileen
Ro, Sunhee
Huang, Jane
Flinn, Ian W.
BLOOD, 2020, 136
[7] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
Kensei Tobinai
Toshiki Uchida
Noriko Fukuhara
Tomoaki Nishikawa
International Journal of Hematology, 2019, 109 : 366 - 368
[8] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
Tobinai, Kensei
Uchida, Toshiki
Fukuhara, Noriko
Nishikawa, Tomoaki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 366 - 368
[9] Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, Anthony R.
Shah, Nirav N.
Jurczak, Wojciech
Cheah, Chan Y.
Pagel, John M.
Woyach, Jennifer A.
Fakhri, Bita
Eyre, Toby A.
Lamanna, Nicole
Patel, Manish R.
Alencar, Alvaro
Lech-Maranda, Ewa
Wierda, William G.
Coombs, Catherine C.
Gerson, James N.
Ghia, Paolo
Le Gouill, Steven
Lewis, David John
Sundaram, Suchitra
Cohen, Jonathon B.
Flinn, Ian W.
Tam, Constantine S.
Barve, Minal A.
Kuss, Bryone
Taylor, Justin
Abdel-Wahab, Omar
Schuster, Stephen J.
Palomba, M. Lia
Lewis, Katharine L.
Roeker, Lindsey E.
Davids, Matthew S.
Tan, Xuan Ni
Fenske, Timothy S.
Wallin, Johan
Tsai, Donald E.
Ku, Nora C.
Zhu, Edward
Chen, Jessica
Yin, Ming
Nair, Binoj
Ebata, Kevin
Marella, Narasimha
Brown, Jennifer R.
Wang, Michael
LANCET, 2021, 397 (10277): : 892 - 901
[10] Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study
Fukuhara, Noriko
Suehiro, Youko
Kato, Harumi
Kusumoto, Shigeru
Coronado, Cinthya
Rappold, Erica
Zhao, Wanying
Li, Jia
Gilmartin, Aidan
Izutsu, Koji
CANCER SCIENCE, 2022, 113 (05) : 1702 - 1711

← 1 2 3 4 5 →